Funapide

Add links
Source: Wikipedia, the free encyclopedia.
Funapide
Clinical data
Routes of
administration		By mouth, topical
ATC code
  • None
Identifiers
  • (7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
JSmol)
  • C1C2(C3=CC=CC=C3N(C2=O)CC4=CC=C(O4)C(F)(F)F)C5=CC6=C(C=C5O1)OCO6
  • InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1
  • Key:NEBUOXBYNAHKFV-NRFANRHFSA-N

Funapide (

topical formulations, and as of July 2014, has reached phase IIb clinical trials.[1][3]

See also

References

  1. ^
    PMID 25060923
    .
  2. ^
    OCLC 1008841684
    .
  3. ^ a b "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders". Xenon Pharma. Archived from the original on 15 July 2013.
  4. ^ a b "Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402". Xenon Pharma. 11 December 2012. Archived from the original on 26 July 2014. Retrieved 2014-07-20.

External links